NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I don’t personally think the reclassification that’s been discussed on this board will impact the DCVax-L RA approval as they will be going for an approval for all newly diagnosed GBM patients, and not some sort of subset of patients. There is no subset defined in the new endpoints… but of course, there’s an entirely new group of patients that have been added… recurrent GBM… which, if stat sig, should increase the initial market potential.

As I see it, Northwest having determined the IDH status can help to eliminate any arguments that the longer living patients were comprised of the typically longer living IDH mutated patients, as it would seem, given that that type of IDH status is usually found in the GBM patients who started with a lesser grade glioma, there would be very few of these types in the trial.